Gustav Boije af Gennäs has extensive experience in the fields of pharmaceutical, organic chemistry, biochemistry and bioanalytics. Gustav has a PhD in pharmaceutical chemistry (University of Helsinki) and a MSc in organic chemistry (University of York & University of Helsinki). He also possesses strong cross-disciplinary expertise in analytical chemistry, biochemistry and inorganic chemistry. He has an exceptionally distinguished career of 16 years at the Technical Research Centre of Finland VTT, the National Institute for Health and Welfare (THL), the Department of Chemistry at the University of Helsinki, and as a postdoctoral researcher in projects with the Academy of Finland.
Before joining the IP sector and Kolster in November 2017, Gustav worked as the team leader and principal researcher of the Drug Discovery unit in the Division of Pharmaceutical Chemistry and Technology at the University of Helsinki.
One of the most significant projects of his career as a researcher was the postdoctoral research project with highly competed funding from the Academy of Finland, in which Gustav developed promising new organic compounds for cancer and Alzheimer’s disease. In a second significant key project with the Academy of Finland, Gustav and his team took part in developing new bioanalytics technologies. During his career, Gustav has also researched compounds for Parkinson’s disease and developed stem cell inducing compounds for use in, for example, the treatment of stroke and myocardial infarction. In 2016, Gustav received the Young Researcher Award from both the University of Helsinki and the Finnish Society of Sciences and Letters. After these recognitions, he was instrumental in the launch of a research project to develop novel methods to inhibit protozoan parasites (causes of e.g. malaria and leishmaniasis).
Gustav has been involved in two patents as an inventor as well as in over 20 scientific publications, and has taught over 15 university courses and supervised several doctoral students.